Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Myeloproliferative Disorders 3Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1

Interventions

ruxolitinib 13Cyclophosphamide 5Tacrolimus 4Stem Cell Transplantation 4Specimen Handling 4fludarabine phosphate 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Cyclosporine 3fludarabine 2fedratinib 2Sirolimus 2Injections 2Busulfan 2Blood Component Removal 2Biopsy 2Azacitidine 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1veliparib 1umbralisib 1thymoglobulin 1selinexor 1reparixin 1piperine 1pevonedistat 1pegylated granulocyte colony-stimulating factor 1navitoclax 1luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × Liposomes × 90 days × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡